Osmotica to Present at Barclays Global Healthcare Conference 2021
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced that CEO Brian Markison and CFO Andrew Einhorn will present at the Barclays Global Healthcare Conference on March 9, 2021, at 9:45 a.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced that CEO Brian Markison and CFO Andrew Einhorn will present at the Barclays Global Healthcare Conference on March 9, 2021, at 9:45 a.m. Eastern Time. The presentation will be available via webcast at this link. Osmotica focuses on developing specialty biopharmaceuticals, with operations in the U.S., Argentina, and Hungary, and offers a diverse portfolio, including products from its ophthalmic subsidiary, RVL Pharmaceuticals.
Details
News Market Reaction – OSMT
The recorded move for OSMT in the trading session of this news was -3.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Barclays Global Healthcare Conference 2021 as follows:
| Date: | Tuesday, March 9, 2021 |
| Time: | 9:45 a.m. Eastern Time |
| Webcast: | https://kvgo.com/2021-global-healthcare-conference/osmotica-march-2021 |
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.